STAT+: Preliminary trial results suggest a path to a safer Alzheimer’s treatment

An interim look at an Alzheimer’s disease clinical trial evaluating an amyloid-targeting treatment from ProMIS Neurosciences showed low rates of brain bleeding and no incidences of brain swelling — results reported Tuesday that suggest the drug could be safer than approved treatments. 

In a blinded analysis that pooled safety data from patients receiving the ProMIS drug and a placebo, the total rate of ARIA was 4.4%, with all cases mild and asymptomatic, the company said. 

None of the patients experienced ARIA-E, which is the more severe side effect that causes brain swelling. All the cases were characterized as ARIA-H, which involves tiny bleeds in the brain. 

Continue to STAT+ to read the full story…

Samsung’s chip workers are jumping ship to rival SK Hynix 

Lee, an engineer at Samsung’s semiconductor division, clocks out when his shift ends. He used to work longer hours, going the extra mile to excel at his projects. But lately, he’s been coming straight home to work on his job application for the chipmaker’s South Korean rival SK Hynix, sharing tips with his coworkers on how to draft a stellar personal statement. Even his boss encourages him to make the move.

“My team lead tells us all to jump ship to SK Hynix,” says Lee. He and his coworkers are feeling demoralized by the $476,000 bonus that SK Hynix is set to pay its employees, flush with record profits from making the high-bandwidth memory (HBM) chips that power Nvidia’s AI accelerators. The figure dwarfs what chip workers at Samsung are set to receive and is sparking an exodus.

As the AI boom heats up, the semiconductor titans are waging a fierce talent war with flashy bonuses, aggressive recruiting, and even a courtroom injunction. Who wins could tilt the race to dominate the next generation of the HBM chips at the heart of the AI boom.

“Except for our two team leads, my entire team [of 30 people] just applied to SK Hynix,” Lee says, referring to a job posting the company published in July. Lee, who has worked at Samsung for three years, even applied for an entry-level position at its rival. A coworker, who has worked at Samsung for eight years, applied for the same one. They both got rejected. But they’re hopeful that they’ll get a callback for a posting seeking a more experienced engineer.

All employees at Samsung and SK Hynix that MIT Technology Review spoke with asked to be identified by just their last name or a pseudonym because they feared retaliation from their employer. Samsung declined to comment, and SK Hynix did not respond to requests for comment.

After prolonged negotiations with its labor union, Samsung struck a deal in May to pay out 10.5% of the semiconductor division’s operating profits to employees as bonuses annually for 10 years, mostly in company stock that vests over three years. The move came after SK Hynix agreed last year to pay out 10% of operating profits to employees, which translates to $476,000 per employee this year—mostly in cash.  

But at Samsung, each division’s bonus is tied to its own bottom line. Chip workers in its memory division, which is also reaping a windfall from making HBM chips, are getting paid a bonus of roughly $400,000 per employee this year. But those who, like Lee, work in Samsung’s foundry division, which manufactures logic chips that companies like Tesla and Google design and has been operating at a loss, are getting a bonus of roughly $135,000. 

Employees told MIT Technology Review that Samsung said it can’t give as many bonuses to divisions that aren’t performing well. Lee, after watching the labor union wrestle with the company for months, says he has felt disappointed by what he ended up with: “Even if Samsung does well in the future, I don’t think any of it will trickle down to me.” 

The workers’ lagging bonuses are making SK Hynix suddenly look appealing. According to a survey by the Samsung labor union in June, 81.5% of employees in the company’s foundry division, and nearly half of employees in the semiconductor division as a whole, said they wanted to go to another company in the next two years. In April, Samsung labor union chief Choi Seung-ho said more than 200 members of the union had left for SK Hynix over the past four months. On Blind, an anonymous workplace forum, a chorus of disgruntled engineers at Samsung confess that they want to defect to SK Hynix for the bigger bonuses. 

For decades, SK Hynix lived in Samsung’s shadow. It was the smaller, scrappier memory maker that elite engineering students at universities looked past when applying for jobs. But in 2019, Samsung downsized its HBM team, betting the market would stay niche, while SK Hynix doubled down on the technology. Then the AI boom supercharged the demand for HBMs, which feed AI chips the enormous amounts of data they need at ultra-high speed, driving prices to unprecedented levels. SK Hynix now leads the global market for HBMs, while Samsung is playing catch-up. Both companies topped $1 trillion in market value in May, and SK Hynix briefly dethroned Samsung as South Korea’s most valuable company in June.

Predicting that demand for memory chips will continue to surge, the semiconductor titans are making aggressive investments to expand their business. Last month, the companies unveiled plans to invest more than $2 trillion by 2040, including a semiconductor “mega-cluster” in Yongin, a city south of Seoul. To staff the expansion, SK Hynix added 2,152 employees in the first half of 2026 alone and aims to double its manufacturing capacity in five years. Samsung plans to hire 60,000 employees over the next five years, especially for its semiconductor division. Even so, the pipeline will fall short: South Korea’s semiconductor industry will need about 304,000 workers by 2031 and faces a shortage of roughly 54,000, according to the Korea Semiconductor Industry Association.

Now the longtime rivals are showering workers with big bonuses to keep—and poach—talent. “[SK Hynix] seems to target Samsung engineers when hiring because it’s a rival,” says Baek, a manager at SK Hynix. “From what I heard internally, the big performance bonuses we got were aimed at luring away talent from our competitor.”

Courts are starting to weigh in. In July, Samsung won an injunction barring two former chip workers from working at SK Hynix for 18 months, on the grounds that chips are a national core technology deserving protection. “With competition in the semiconductor industry fierce, it’s necessary to establish a fair market order,” the court ruled.

The talent exodus threatens a crucial advantage that Samsung still holds in the HBM race. “Samsung is the only memory maker in the world that owns a foundry business,” says Park Jun-young, a semiconductor expert at the Industrial Anthropology Laboratory, a research institute, who worked at Samsung for a decade. 

With the latest generation of the technology, known as HBM4, the logic chip at the base of each memory stack must be manufactured with the kind of advanced process that only foundries run. Samsung can do this in-house, while SK Hynix outsources it to the Taiwanese foundry giant TSMC. “If Samsung keeps losing engineers in the foundry … the collaboration between memory division and foundry division could become difficult,” says Park. “SK Hynix, which used to have only a memory team and is now hiring foundry engineers, could do better research on HBMs.”

Choi, an engineer who has worked at Samsung for seven years, says he was once a star on his team, getting glowing performance reviews from his managers. But lately, he and his coworkers have been busy applying for every SK Hynix job posting they see. “We tell each other when the next SK Hynix job posting is up,” he says. “There’s always more work to do beyond our basic duties. But there’s no point in doing it.”

Opinion: STAT+: Dementia finally has a business model

In the nine years since my last visit to the Docklands’ Excel conference center for the 2017 annual Alzheimer Association International Conference, or AAIC, little of London’s infrastructure has changed. I traveled via the same low-ceilinged, clattering trains with signs advising riders to “mind the gap” and “mind the step.” The center has the same weird jack-o’-lantern-esque façade and forgettable restaurants and hotels. I was even here for the same conference.

Same meeting, in the same place, but what transpired was quite different. In just nine years, how we think about the aging brain has transformed.

One moment captured this. It was a speaker’s remark at a breakfast meeting convened by the Davos Alzheimer’s Collaborative. The 5-year-old organization describes itself as “uniting leading organizations worldwide to build an innovation ecosystem that will accelerate breakthroughs, develop and scale promising solutions and equip every healthcare system to end Alzheimer’s disease everywhere.”

Continue to STAT+ to read the full story…

STAT+: From ‘lost cause’ to gold rush: Biotechs swarm to cure AATD 

Biotechs are spending billions to cure a rare liver disorder most Americans have never heard of. The contentious race features dueling technologies, patent wars, a broken alliance, and a boiling competition between the U.S. and Chinese drug industries.

The disease, known as alpha-1 antitrypsin deficiency (AATD), is a slow-moving disaster for patients. Thanks to a single misspelled letter of DNA, their livers produce a mutant version of a protein that normally travels through the bloodstream and protects the lung from damage. 

Continue to STAT+ to read the full story…

STAT+: CMS evaluates one year of health tech progress, announces eight new pledge categories

It was a skit worthy of an Agatha Christie whodunit reveal: Against the perhaps-too-joyous strains of a jazzy “When The Saints Go Marching In,” a gaggle of health IT professionals and Medicare staffers accompanied a Spirit Halloween-style coffin prop onstage at Health and Human Services headquarters on Monday. Some wore black veils, some held white roses. 

The coffin read, “RIP CLIPBOARD,” referring to the decades-old information-gathering staple of health care provider waiting rooms.

“So who killed the clipboard?” asked Zac Jiwa, a federal Medicare official. Health IT officials and experts, reading from cue cards, denied that it was standards implementation, health information exchange networks, electronic health records, or apps — all parts of the various health data initiatives that private industry promised Medicare a year ago that it would improve.

Continue to STAT+ to read the full story…

Structuring Digital Mental Health Care Navigation: Co-Design Nominal Group Technique Study to Develop the MChart Definition and Typology of the Characteristics of Digital Mental Health Care Navigation Tools

<strong>Background:</strong> Australia’s mental health care system has been characterized by complexity and fragmentation, as highlighted by numerous reports, commissions, and inquiries. In response, digital mental health care navigation tools have emerged as a promising solution to help individuals locate appropriate mental health services. The rapid proliferation of these tools—without a clear understanding of their definitions and characteristics—risks creating confusion rather than clarity for users. Terms such as “navigation” and “navigators” are often used interchangeably, further complicating the landscape. <strong>Objective:</strong> This study addressed the need for a standardized definition and typology of the characteristics of digital mental health care navigation tools. <strong>Methods:</strong> This study was part of the development of a digital mental health care navigation tool for navigators and planners (MChart). It used a co-design approach using expert-based cooperative analysis, which is a nominal group technique to develop a definition and typology of the characteristics of digital mental health care navigation tools. This process was guided by the Technology Readiness Level for Implementation Sciences framework. The co-design process involved two 2-hour sessions with an expert panel comprising 28 participants, including representatives from mental health planning, primary health care, health care financing and delivery, community-managed organizations, clinical settings (psychiatrists, psychologists, and general practitioners), and consumers. <strong>Results:</strong> The expert panel collaboratively developed a consensus definition of digital mental health care navigation tools, outlining their scope and intended targets. Through the co-design process, the panel identified 157 characteristics of digital mental health care navigation tools. These characteristics were organized into 5 primary domains: type, management, content, design, and quality. The definition and typology characteristics provide a structured framework for understanding and evaluating the diverse range of digital mental health care navigation tools currently available. <strong>Conclusions:</strong> The co-designed definition and typology offer a foundational step toward reducing confusion in the digital mental health care navigation space. This study supports the development of quality standards that can be used to assess and compare existing and future tools. This framework has the potential to guide developers, end users, and policymakers in creating more effective, user-centered navigation solutions within Australia’s mental health care system and internationally.

STAT+: HIV resurgence is feared as global funding to combat the disease falls 18%

The world risks a resurgence of the HIV epidemic after international financing to combat the infectious disease suffered a “profound shock” last year, according to a new report from UNAIDS, the United Nations agency.

Overall, government funding declined by more than $1.5 billion to $7.3 billion in 2025 — an 18% decline and the lowest level in nearly two decades. Prevention programs, in particular, have historically relied heavily on donor assistance in most regions, with especially high dependency in sub-Saharan Africa, where it reached 83% two years ago.

Other factors contributing to the worrisome outlook are high debt burdens in countries most affected by the disease and backsliding on human rights and gender equality, the report noted.

Continue to STAT+ to read the full story…

Mobility Patterns and Mental Health During the COVID-19 Pandemic: Longitudinal Observational Study Using Smartphone Mobility Data

<strong>Background:</strong> The COVID-19 pandemic disrupted mobility globally, but its mental health implications remain difficult to characterize because most studies relied on lockdown status, population-level mobility indicators, or self-reported mobility. These approaches may miss individual differences in actual movement patterns and cannot fully examine bidirectional relationships between mobility and mental health. Individual-level smartphone geolocation data may provide a more objective and temporally aligned measure of mobility during periods of societal disruption. <strong>Objective:</strong> This study aimed to use individual-level Google location history (GLH) data and population-level Google community mobility reports (GCMRs) to examine concurrent and longitudinal relationships between pandemic-era mobility patterns and mental health symptoms in Hong Kong. <strong>Methods:</strong> This study analyzed data from the CU-COVID19 cohort study, an online longitudinal survey study of the psychological impact of the pandemic in Hong Kong. Mental health symptoms over the previous 14 days were assessed at baseline, 6 months, and 12 months using the 9-item Patient Health Questionnaire, the 7-item Generalized Anxiety Disorder scale, and the 4-item PTSD Checklist for DSM-5. Participants provided retrospective GLH data reflecting their mobility during the corresponding 14-day survey periods. The analytic sample included 145 participants with baseline GLH data, of whom 110 had 6-month follow-up data and 49 had data available at all 3 assessment waves. GLH data were used to derive mobility factors representing journey diversity, immobility, and remoteness. Population-level mobility during the same 14-day periods was measured using Hong Kong GCMR residential stay data. Concurrent mediation models examined whether individual mobility mediated associations between population-level residential stay and mental health symptoms. Longitudinal models examined bidirectional associations between changes in individual mobility and mental health across 6-month intervals. <strong>Results:</strong> Population-level residential stay was not directly associated with mental health. In concurrent mediation models, higher population-level residential stay was associated with lower individual journey diversity (β=–0.36; <i>P</i>&lt;.001), and lower journey diversity was associated with higher depression (β=–0.29; <i>P</i>=.02) and posttraumatic stress disorder (PTSD) (β=–0.35; <i>P</i>=.002). Bootstrapped indirect effects suggested mediation through journey diversity for depressive symptoms (β=0.11, 95% CI 0.02-0.25) and PTSD symptoms (β=0.13, 95% CI 0.05-0.27), although the depression-related indirect effect became less robust after adjustment for local and individual COVID-19 infection indicators. Longitudinally, higher baseline depressive symptoms predicted subsequent reductions in journey diversity (β=–0.15; <i>P</i>=.02), and reductions in journey diversity predicted higher subsequent depressive symptoms (β=–0.43; <i>P</i>=.008). <strong>Conclusions:</strong> Individual-level mobility patterns, particularly lower journey diversity, showed more consistent associations with mental health symptoms than population-level residential stay. Findings suggest bidirectional relationships between mobility and mental health and demonstrate the potential of smartphone geolocation data for digital phenotyping. However, the modest and self-selected sample, limited GCMR availability, and observational design require cautious interpretation.

MapLight’s Schizophrenia Candidate Has Mixed Results at Phase II

MapLight Therapeutics announced this week that its candidate drug for treatment of schizophrenia had achieved its primary endpoint in a Phase II trial, but only at the twice daily dose tested in the trial.

As reported by the California-based company, while participants of the trial who were given the candidate drug, ML-007C-MA, once a day did show some signs of improvement it was not statistically significant.

ML-007C-MA is a combined muscarinic agonist (betovumeline) and peripherally acting anticholinergic (fesoterodine). It acts by turning on two receptors in the brain, M1 and M4.

M1 is the main receptor the drug is trying to stimulate in the brain cortex and hippocampus, where it is linked to cognition, attention, and possibly some aspects of psychosis. Turning on M4 also helps by acting like a brake on the overactive signaling that contributes to hallucinations and delusions. Betovumeline activates both M1 and M4 centrally, while fesoterodine is there mainly to block unwanted side effects outside the brain, like gastrointestinal issues.

In this study, MapLight randomized 307 adults with an acute exacerbation of schizophrenia to treatment with either a twice daily or once daily treatment with ML-007C-MA or placebo for five weeks.

At five weeks, patients given the twice daily dose had a statistically significant and clinically meaningful reduction in Positive and Negative Syndrome Scale (PANSS) total score of 4.5 points compared to placebo. Cognitive scores were also better in the twice daily group versus placebo.

While this result is positive overall, the non-statistically significant result for the once daily dose proved unpopular with investors and company shares on the Nasdaq fell 40% after the announcement.

In September 2024, Cobenfy, the first muscarinic M1/M4 agonist drug for treatment of schizophrenia was approved by the FDA. Now owned by BMS, Cobenfy will be the main competitor for ML-007C-MA if approved.

Cobenfy was groundbreaking because it was the first new mechanism of action for schizophrenia in decades, moving beyond dopamine blockade to a muscarinic approach and targeting both hallucinations and delusions as well as the more cognitive aspects of the disease, which are not well treated with other drugs.

Despite the approval of Cobenfy, a number of other competitors developing treatments for schizophrenia have failed in recent years. Whether MapLight can succeed at Phase III with ML-007C-MA—which is also being tested as a treatment for psychosis linked to Alzheimer’s disease—and compete with Cobenfy, remains to be seen.

The post MapLight’s Schizophrenia Candidate Has Mixed Results at Phase II appeared first on Inside Precision Medicine.